Nektar Corp (NKTR) - מקדם חוב לטווח ארוך להון

Nektar Therapeutics (NKTR) generates revenue through the sale of proprietary drug delivery systems, grants, and licensing royalties for developments in oncology and immunology. The business maintains geopolitical stability due to the humanitarian status of its research and its localization within Western jurisdictions. The company is currently optimizing expenses and developing a promising dermatitis drug in collaboration with Eli Lilly, which is recorded at 0.14. The asset's price trajectory is illustrated in the chart below.

This ratio compares liabilities with a maturity of over one year to equity value, determining the business's degree of dependence on external debt financing. Amid geopolitical risks for Nektar Therapeutics (NKTR) and the complexity of clinical trials, the long-term debt-to-equity trend confirms the company's ability to maintain operational autonomy without a critical debt burden.